While this series was too small to find a statistically significant effect of topical corticosteroid on biopsy result, it may be prudent to discontinue topical corticosteroid prior to conjunctival biopsy to optimize biopsy yield, although the ideal length of time of discontinuation is yet to be determined.
Yet, discontinuation occurs frequently and relatively soon after initiation of cinacalcet treatment, on average within 4 months following initiation, Additional file 1: Table S7.
Yet, early discontinuation of cinacalcet was frequent and resulted in the loss of control of PTH, calcium, and phosphorus.
The choice of 36 weeks for the RCT therefore: a) covers the period of greatest risk of relapse of PD following the discontinuation of the antipsychotic, yet allows for a period of observation beyond that time, b) saves on the cost that would be associated with a longer study, and c) allows the study to be completed within 5 years in the four collaborating sites.
Interestingly, 12 patients had radiographic evidence for intracranial hemorrhage prior to receiving bevacizumab, yet only 1 patient required discontinuation of bevacizumab due to progression of hemorrhage.
In the ATTRACT study, the combination of infliximab and methotrexate over 30, 54, and 102 weeks provided significant, clinically relevant improvement in a majority of patients with RA who had an incomplete response to methotrexate alone; however, discontinuation rate data at 102 weeks have yet to be made available [ 11- 13].
One patient received 12 cycles, discontinued the study for an unrelated medical condition and, at the time of discontinuation, had an increase in tumour size not yet reaching disease progression.
In fact, 20 participants had only had one follow-up visit by the time of discontinuation, yet 12 of these completed their remaining eleven months of follow-up.
The current policies of TKI treatment of chronic phase CML mandate using TKIs at their respective approved or maximum tolerated doses lifelong, with the possibility of opening a window for treatment discontinuation when a DMR has been achieved and maintained for an as yet unspecified period of time.
Preliminary, yet unpublished, data from our department support the possibility of gradual drug discontinuation in responders.
Yet, a distinct signal towards a possible increase of ischaemic events after discontinuation of clopidogrel at six months has been specifically observed after sirolimus or paclitaxel eluting stents but not after cobalt-chromium everolimus eluting stents.
